Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250009/S002

SQUID Liquid Embolic Agent (LEA)

Balt USA, LLC · Decision date Sep 9, 2026

MEDTECHLEDGER EXPLANATIONP250009/S002

What did the FDA approve?

The FDA record for P250009/S002, dated 2026-09-09, shows an approval for changes to the mixing time for the SQUID Liquid Embolic Agent (LEA). It is classified as a real-time process supplement under the labeling-change reason covering indications, instructions, shelf life, or tradename. The record lists the device category as a neurovascular liquid embolic agent and the specialty as neurology, with Balt USA, LLC as applicant. The specific before-and-after mixing times are not given in the supplied fields.

The S002 identifier links the action to the preceding PMA P250009 as a supplement, not a new approval of the whole system. The record's reported purpose describes a process change to mixing time; it does not establish safety or clinical effectiveness independently. The supplied fields also omit whether the change is accompanied by revised labeling text, what prompted the change, and which shelf-life or instruction sections were affected.

The supplement type is listed as "Real-Time Process," and the stated purpose is confined to the mixing time, so no broader technical detail, trial result, or new indication should be inferred from this entry.

FDA approval order statement

Approval for changes to the mixing time for the SQUID Liquid Embolic Agent (LEA).
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Sep 9, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250009/S002
Regulatory pathway
PMA supplement
Applicant
Balt USA, LLC
Product code
SGU
Decision code
APPR
Decision date
Sep 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Neurovascular Liquid Embolic Agent.

Applicant
Balt USA, LLC
Product code
SGU
FDA device class
3

For the original device and its historical approval scope, see PMA P250009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250009 · Original PMA

    SQUID Liquid Embolic Agent (LEA)

  2. P250009/S002 received

    Application receipt date recorded by FDA.

  3. P250009/S002 · FDA decision

    Real-Time Process

  4. P250009/S001 · Related supplement

    SQUID Liquid Embolic Agent (LEA)

Timeline entries are records held by MedtechLedger for P250009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250009

Product / regulatory recordCompanyPathwayDecision dateSource
Balt USA, LLCPMA approvalJan 30, 2026FDA
Balt USA, LLCPMA supplementOct 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Balt USA, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
29 Parker, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records